Newsroom

The work, as it moves forward.

Company announcements, research perspectives, and updates on the Clarity+ platform.

Clarity+ Home Interface arranged on a minimal docking tray

Product update Clarity+ Home

Vale Biotech introduces at-home maintenance for enrolled Clarity+ customers.

The five-module Home Interface extends individualized, low-power maintenance beyond certified treatment centers after clinical onboarding.

Read the announcement

Vale Biotech today introduced the Clarity+ Home Interface, a compact maintenance system for customers who have completed NeuroTag priming, guided-recall mapping, supervised intervention, and in-clinic onboarding.

The device replays low-power waveforms prepared for each enrolled profile. It does not perform the one-time primer, create an individual map, or initiate the clinical intervention.

"Access should not end at the treatment-room door," said Richard Vale, co-founder and chief executive officer. "Clarity+ Home carries a personalized plan into the reality of daily life."

Latest from Vale

Announcements and perspectives.

Company announcement Global launch

Vale Biotech unveils Clarity+, a new platform for cognitive restoration.

The platform brings together more than a decade of work in NeuroTag priming, individual recall mapping, and precision-guided reconsolidation.

Clarity+ was introduced to clinical partners as one connected course of personalized care. Early participants have described renewed access to familiar routines, relationships, and independence.

Global access programs are beginning with certified partners in Europe and Japan alongside continued expansion of Vale Biotech treatment centers.

Neural imaging displays inside the Vale Biotech research laboratory

Research note Continuity

Why a restorative system must leave room for more than one answer.

The Ellison Continuity Constraint treats contradiction and the capacity to revise as features of identity, not noise.

Vale Biotech co-founder Dr. Robert Ellison argued that functional recovery alone cannot establish continuity. A restorative system must also preserve multiple viable pathways through memory, emotion, and choice.

Dr. Mara Ellison translated that principle into the measurable stability window at the center of the Clarity+ research platform.

Richard Vale, co-founder and chief executive officer of Vale Biotech

Leadership From the CEO

"The distance between discovery and access is a problem we can solve."

Richard Vale on the work required to move important cognitive science beyond the laboratory.

"Robert and I founded Vale Biotech because no single discipline could answer the questions in front of us. That remains true. A model needs engineering. Engineering needs clinical judgment. Clinical judgment must remain accountable to the person."

"Clarity+ is only the beginning of what becomes possible when those disciplines move together."

Media resources

About Vale Biotech

Vale Biotech is an interdisciplinary cognitive-technology company founded by Richard Vale and Dr. Robert Ellison. Its public mission is to restore cognitive function, expand access to care, and preserve the person within every measure of recovery.

For readers and media: Vale Biotech is a fictional company from the novel Clarity+ by Kristian Millirons.

Visit the official book site